جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

20 مُخرَج نتائج البحث عن «Drug development»

مقالوصول مفتوح2026

In silico assessment of catenulopyrizomicin A and B as potential inhibitors of HCV NS3/4A protease

Discover Applied Sciences

The hepatitis C virus (HCV) has no vaccine, and available therapies are linked to adverse outcomes, high costs and emergence of resistance. A previous study have identified catenulopyrizomicin A and B as bioactive compounds from natural products with reported antiviral properties, warranting further evaluation against the HCV NS3/4A protease using non-in silico methods. The aim of this study was to evaluate the anti-HCV potentials of catenulopyrizomicins A and B against 5EQS, a genotype 1a/3a chimeric HCV NS3/4A protease of HCV using in silico approaches. In this study, the anti-HCV potential of catenulopyrizomicin A and B was evaluated using in silico approaches (molecular docking, simulation, ADMET profiling, and DFT) with ribavirin as a control, and 5EQS as the target protein (NS3/4A). Docking scores for the ligands were − 5.8, − 5.8, and − 6.1 kcal/mol, respectively, for catenulopyrizomicin B, ribavirin, and catenulopyrizomicin A. Two dimensional (2D) visualisation of the formed complexes revealed the dominance of Van der Waals forces and polar interactions between the ligands and the target protein. Molecular dynamics simulations revealed variations in RMSD and RMSF that indicated that the formed stable complexes with values that remained below 2.0 Å throughout most of the simulation runs, indicating stability. Ligand-protein contact analysis revealed the presence of conserved residues, including Gln1041, Thr1042, His1057, Arg1109, Leu1132, Leu1135, Lys1136, and Cys1159 across the test ligands, suggesting that they may be important in ligand recognition and foramtion of stable interactions. ADMET properties revealed that catenulopyrizomicin A and B had better intestinal absorption rates (36.41% and 36.28%) than ribavirin (30.95%), as well as good distribution, as revealed by their better VDss values (− 0.53 to − 0.61 for catenulopyrizomicin A and B) compared to ribavirin which was − 0.22. The DFT results showed that catenulopyrizomicin A and B were more reactive and nucleophilic than ribavirin. The findings suggest that catenulopyrizomicin A and B may serve as potential lead compounds for anti-HCV drug development. However, further in vitro and in vivo studies are required to validate their antiviral activity and pharmacological properties.

hepatitis C virusNS3/4A proteaseprotease inhibitorsmolecular docking
مراجعةمفتوح (مستودع)202542استشهاد· Semantic Scholar

Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies

Food Science & Nutrition · مجلد 13 (1) · e4682-e4682

Luteolin is widely distributed phytochemical, a flavonoid, in kingdom plantae. Luteolin with potential antioxidant activity prevent ROS-induced damages and reduce oxidative stress which is mainly responsible in pathogenesis of many diseases. Several chemo preventive activities and therapeutic benefits are associated with luteolin. Luteolin prevents cancer via modulation of numerous pathways, that is, by inactivating proteins; such as procaspase-9, CDC2 and cyclin B or upregulation of caspase-9 and caspase-3, cytochrome C, cyclin A, CDK2, and APAF-1, in turn inducing cell cycle arrest as well as apoptosis. It also enhances phosphorylation of p53 and expression level of p53-targeted downstream gene. By Increasing BAX protein expression; decreasing VEGF and Bcl-2 expression it can initiate cell cycle arrest and apoptosis. Luteolin can stimulate mitochondrial-modulated functions to cause cellular death. It can also reduce expression levels of p-Akt, p-EGFR, p-Erk1/2, and p-STAT3. Luteolin plays positive role against cardiovascular disorders by improving cardiac function, decreasing the release of inflammatory cytokines and cardiac enzymes, prevention of cardiac fibrosis and hypertrophy; enhances level of CTGF, TGFβ1, ANP, Nox2, Nox4 gene expressions. Meanwhile suppresses TGFβ1 expression and phosphorylation of JNK. Luteolin helps fight diabetes via inhibition of alpha-glucosidase and ChE activity. It can reduce activity levels of catalase, superoxide dismutase, and GS4. It can improve blood glucose, insulin, HOMA-IR, and HbA1c levels. This review is an attempt to elaborate molecular targets of luteolin and its role in modulating irregularities in cellular pathways to overcome severe outcomes during diseases including cancer, cardiovascular disorders, diabetes, obesity, inflammation, Alzheimer's disease, Parkinson's disease, hepatic disorders, renal disorders, brain injury, and asthma. As luteolin has enormous therapeutic benefits, it could be a potential candidate in future drug development strategies.

luteolinflavonoidsantioxidant activityanticancer activity
مقالوصول مفتوح20255استشهاد· Semantic Scholar

Exploration of effective pharmacological inhibitors for NS5 protein through computational approach: A strategy to combat the neglected Kyasanur forest disease virus

PLoS ONE · مجلد 20 (7) · e0325613-e0325613

Kyasanur Forest Disease Virus (KFDV) poses a significant public health threat due to the limited efficacy of existing vaccines, necessitating the development of effective antiviral therapeutics. The nonstructural protein 5 (NS5), essential for viral RNA synthesis and methylation, serves as a promising drug target. This study employs computational approaches to identify and evaluate potential NS5 inhibitors that may contribute to the development of antiviral compounds against KFDV. The 3D structure of NS5 was predicted using Robetta, SwissModel, and I-TASSER, with the Robetta model (ERRAT score: 96.40) selected for energy minimization. The globally minimized structure, obtained at 49.58 ns, had a potential energy of -416966.82 kcal/mol and was used for further studies. Active site residues were identified using template-based and structure-based methods (COACH-D, CASTp, PrankWeb) and were located within polymerase motif (A-G) of NS5 protein (residues 273-903 aa), which are essential for polymerase function, RNA synthesis, and viral replication. A total of 1523 compounds were identified using de novo, template-based design, pharmacophore modeling, and ligand screening. Virtual screening with PyRx 0.8 yielded 34 promising compounds, of which 11 were selected based on molecular docking (AutoDock 4.0) with binding energies of -8.86 kcal/mol (FDA-approved dasabuvir -L1), -8.28 kcal/mol (CNPO331352.1-L2), -7.94 kcal/mol (ZINC00103114410- L3), and -7.61 kcal/mol (CNPO202263.1-L4). MD simulations in triplicates under physiological conditions confirmed stability. with MM-GBSA binding free energy values of -52.28 ± 2.91 kcal/mol (NS5-Dasabuvur L1complex), -46.82 ± 4.31 kcal/mol (NS5-L2 complex), -50.72 ± 6.36 kcal/mol (NS5-L3 complex), and -57.03 ± 4.31 kcal/mol (NS5-L4 complex). The computational analysis suggests that compounds L2 and L4 have strong binding affinities comparable to dasabuvir (L1), indicating their potential as inhibitors of the KFDV NS5 protein. Further validation through in vitro assays would complement these in silico findings. These results provide a foundation for future drug development against KFDV, emphasizing the need for continued exploration of antiviral therapeutics.

Kyasanur forest disease virusNS5 proteinRNA-dependent RNA polymeraseantiviral drug design
مقالوصول مفتوح20251استشهاد· Semantic Scholar

Exploring phytochemicals as potential pharmacological inhibitors for NS1 protein of Kyasanur forest disease virus using virtual screening, molecular docking, and molecular simulation approach

PeerJ · مجلد 13 · e19954-e19954

Background: Kyasanur forest disease virus (KFDV) remains a significant public health challenge due to the limitations of existing vaccines, creating a critical need for effective antiviral treatments. KFDV is a tick-borne virus responsible for 400-500 new cases annually, with a mortality rate of 3-5%. The nonstructural protein 1 (NS1), which plays crucial roles in host cell interactions, immune evasion, and viral replication, represents a promising target for antiviral drug development. Objective: This study aims to identify potential antiviral compounds that inhibit the activity of KFDV NS1 protein using a computational pharmacological drug design approach. The objectives include determining the 3D structure of the NS1 protein through homology modeling, conducting virtual screening of phytochemicals to identify potential inhibitors, and performing molecular dynamics simulations to assess the stability and binding free energies of the selected compounds. Methods: The 3D structure of KFDV NS1 protein was predicted using homology modeling and validated using Ramachandran plot analysis. Virtual screening of phytochemicals from the Indian Medicinal Plants, Phytochemistry And Therapeutics (IMPPAT) database was performed to identify potential NS1 inhibitors. The top 15 compounds with the highest binding affinities were selected and subjected to absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis. Molecular dynamics simulations were conducted in duplicates for 200 ns to evaluate the stability of the ligand-NS1 complexes, and an additional independent simulation with randomized initial velocities was performed to ensure statistical robustness. Binding free energies were calculated using the molecular mechanics-generalized born surface area (MM-GBSA) method to determine the binding strength of each compound. Results: The 3D structure of the KFDV NS1 protein was determined using I-Tasser-MTD, Robetta, and Swiss Model servers, and a minimized model of I-Tasser, achieving an ERRAT score of 94.37, was selected. Virtual screening of 11,530 phytochemicals from the IMPPAT database identified the top 115 compounds after three screening phases. Out of the 15 screened compounds, L2, L3, and L5 demonstrated notable binding affinities of -9.34, -9.12, and -9.08 kcal/mol, respectively, compared to the FDA-approved antiviral dasabuvir, which had a binding affinity of -8.0 kcal/mol. Molecular dynamics simulations confirmed the stability of compounds L2 (IMPHY010294), L3 (IMPHY001281), L5 (IMPHY011162), and dasabuvir, with free-energy binding values of -62.97 ± 4.0, -77.22 ± 4.71, -62.07 ± 2.88, and -87.68 ± 4.31 kcal/mol, respectively. Conclusion: findings.

Kyasanur forest disease virusNS1 proteinantiviral drug designphytochemicals
مقالوصول مفتوح202412استشهاد· Semantic Scholar

Repurposing FDA-approved drugs for COVID-19: targeting the main protease through multi-phase in silico approach

Antiviral Therapy · مجلد 29 (6) · 13596535241305536-13596535241305536

Background The COVID-19 pandemic has created an urgent need for effective therapeutic agents. The SARS-CoV-2 Main Protease (M pro ) plays a crucial role in viral replication and immune evasion, making it a key target for drug development. While several studies have explored M pro inhibition, identifying FDA-approved drugs with potential efficacy remains a critical research focus. Purpose This study aims to identify FDA-approved drugs that could inhibit SARS-CoV-2 M pro . Using computational screening, we seek compounds that share structural similarities with a known co-crystallized ligand (PRD_002214) and exhibit strong binding affinity to the enzyme, providing viable candidates for COVID-19 treatment. Research Design A systematic in silico approach was used, screening 3009 FDA-approved drugs. The initial screening focused on structural similarity to PRD_002214 (PDB ID: 6LU7), followed by molecular docking studies to predict binding affinity. Promising compounds were further analyzed through molecular dynamics (MD) simulations to evaluate their stability and interactions with M pro over 100 ns. Study Sample Of the 3009 FDA-approved drugs screened, 74 were selected for initial evaluation. After refinement, 28 compounds underwent docking analysis, with eight showing strong binding potential to M pro . Analysis Molecular docking assessed the binding affinity and interaction of the selected compounds with M pro . MD simulations were conducted on the top compound, Atazanavir, to study its dynamic interactions. MM-GBSA, PLIP, and PCAT analyses were used to validate binding affinity and interactions. Results Eight compounds, including Carfilzomib, Atazanavir, Darunavir, and others, exhibited promising binding affinities. Among them, Atazanavir showed the highest binding strength and was selected for further MD simulation studies. These simulations revealed that Atazanavir forms stable interactions with M pro , demonstrating favorable binding and dynamic stability. The binding affinity was further confirmed through MM-GBSA, PLIP, and PCAT analyses, supporting Atazanavir's potential as an effective M pro inhibitor. Conclusions In silico results suggest that Atazanavir is a promising candidate for targeting SARS-CoV-2 M pro , with strong binding affinity and dynamic stability. These findings support its potential as a lead compound for further preclinical and clinical testing, though in vitro and in vivo validation are needed to confirm its therapeutic efficacy against COVID-19.

COVID-19 pandemicmain proteaseMpro inhibitorsFDA-approved drugs
مقالوصول مفتوح202412استشهاد· Semantic Scholar

Structure-based discovery of F. religiosa phytochemicals as potential inhibitors against Monkeypox (mpox) viral protein

Journal of Biosafety and Biosecurity · مجلد 6 (3) · 157-169

Outbreaks of Monkeypox (mpox) in over 100 non-endemic countries in 2022 represented a serious global health concern. Once a neglected disease, mpox has become a global public health issue. A42R profilin-like protein from mpox (PDB ID: 4QWO) represents a potential new lead for drug development and may interact with various synthetic and natural compounds. In this report, the interaction of A42R profilin-like protein with six phytochemicals found in the medicinal plant Ficus religiosa (abundant in India) was examined. Based on the predicted and compared protein-ligand binding energies, biological properties, IC50 values and toxicity, two compounds, kaempferol (C-1) and piperine (C-4), were selected. ADMET characteristics and quantitative structure-activity relationship (QSAR) of these two compounds were determined, and molecular dynamics (MD) simulations were performed. In silico examination of the kaempferol (C-1) and piperine (C-4) interactions with A42R profilin-like protein gave best-pose ligand-binding energies of –6.98 and –5.57 kcal/mol, respectively. The predicted IC50 of C-1 was 7.63 μM and 82 μM for C-4. Toxicity data indicated that kaempferol and piperine are non-mutagenic, and the QSAR data revealed that piperlongumine (5.92) and piperine (5.25) had higher log P values than the other compounds examined. MD simulations of A42R profilin-like protein in complex with C-1 and C-4 were performed to examine the stability of the ligand-protein interactions. As C-1 and C-4 showed the highest affinity and activities, they may be suitable lead candidates for developing mpox therapeutic drugs. This study should facilitate discovering and synthesizing innovative therapeutics to address other infectious diseases.

monkeypoxFicus religiosaphytochemicalskaempferol
مقالوصول مفتوح202411استشهاد· Semantic Scholar

DFT and molecular simulation validation of the binding activity of PDEδ inhibitors for repression of oncogenic k-Ras

PLoS ONE · مجلد 19 (3) · e0300035-e0300035

The development of effective drugs targeting the K-Ras oncogene product is a significant focus in anticancer drug development. Despite the lack of successful Ras signaling inhibitors, recent research has identified PDEδ, a KRAS transporter, as a potential target for inhibiting the oncogenic KRAS signaling pathway. This study aims to investigate the interactions between eight K-Ras inhibitors (deltarazine, deltaflexin 1 and 2, and its analogues) and PDEδ to understand their binding modes. The research will utilize computational techniques such as density functional theory (DFT) and molecular electrostatic surface potential (MESP), molecular docking, binding site analyses, molecular dynamic (MD) simulations, electronic structure computations, and predictions of the binding free energy. Molecular dynamic simulations (MD) will be used to predict the binding conformations and pharmacophoric features in the active site of PDEδ for the examined structures. The binding free energies determined using the MMPB(GB)SA method will be compared with the observed potency values of the tested compounds. This computational approach aims to enhance understanding of the PDEδ selective mechanism, which could contribute to the development of novel selective inhibitors for K-Ras signaling.

PDEδKRAS inhibitorsoncogenic KRASbinding free energy
مقالوصول مفتوح202410استشهاد· Semantic Scholar

Computational exploration of Picrasma quassioides compounds as CviR-mediated quorum sensing inhibitors against Chromobacterium violaceum

Frontiers in Chemistry · مجلد 12 · 1286675-1286675

Chromobacterium violaceum an opportunistic human pathogenic bacterium, exhibits resistance to conventional antibiotics by exploiting its quorum sensing mechanism to regulate virulence factor expression. In light of this, disrupting the quorum sensing mechanism presents a promising avenue for treating infections caused by this pathogen. The study focused on using the cytoplasmic quorum sensing receptor CviR from C. violaceum as a model target to identify novel quorum sensing inhibitors from P. quassioides through in silico computational approaches. Molecular docking analyses unveiled that several phytochemicals derived from Picrasma quassioides exhibit the potential to inhibit quorum sensing by binding to CviR protein. Notably, the compounds such as Quassidine I (– 8.8 kcal/mol), Quassidine J (– 8.8 kcal/mol), Kumudine B (– 9.1 kcal/mol) and Picrasamide A (– 8.9 kcal/mol) exhibited high docking scores, indicating strong binding affinity to the CviR protein. The native ligand C6-HSL (N-hexanoyl-L-homoserine lactone) as a positive control/co-crystal inhibitor also demonstrated a significant binding energy of—7.7 kcal/mol. The molecular dynamics simulation for 200 ns showed the thermodynamic stability and binding affinity refinement of the top-ranked CviR inhibitor (Kumudine B) with its stable binding and minor fluctuations compared to positive control (C6-HSL). Pharmacokinetic predictions indicated that Kumudine B possesses favourable drug-like properties, which suggest its potential as a drug candidate. The study highlight Kumudine B as a potential agent for inhibiting the CviR protein in C. violaceum. The comprehensive evaluation of Kumudine B provides valuable insights into its pharmacological profiles, facilitating its assessment for diverse therapeutic applications and guiding future research activities, particularly as antibacterial agents for clinical drug development.

Picrasma quassioidesChromobacterium violaceumquorum sensing inhibitionphytochemicals
مقالمفتوح (مستودع)20241استشهاد· Semantic Scholar

An evaluation of the precision of computational methods used in drug development initiatives

Journal of Biomolecular Structure and Dynamics · مجلد 44 (5) · 2235-2249

Computational approaches are commonly employed to expedite and provide decision-making for the drug development process. Drug development programs that involve targets without known crystal structures can be quite challenging. In many cases, a viable approach is to generate reliable homology models using the amino acid sequence of the target. This is followed by a series of validation steps, druggable pocket detection, and then moving forward with lead identification and validation. This study commenced by conducting an initial benchmark exercise using a series of computationally designed sequences for steroid-binding proteins. By conducting an unbiased comparison with the released X-ray crystal structures, the homology models that were generated demonstrated reliable outcomes. The aligned homology models showed a root mean square deviation (RMSD) of less than 0.6 Å when compared to the corresponding X-ray structures. Three different methods were used to detect the druggable cavities for comparison, and the identified pockets closely resembled those of the crystal structures. The achievement of near-native pose prediction was made possible by utilizing the comprehensive binding energy function that characterizes the interaction between each pose and the neighboring residues. In order to address the issue of limited correlation between entropy and internal energy in docking, an alternative was devised by incorporating entropy as a post-docking optimization step to enhance the accuracy of ligand binding affinity predictions and improve the overall quality of the results.

homology modelingsteroid binding proteinsmolecular dockingbinding affinity prediction
مقالوصول مفتوح202313استشهاد· Semantic Scholar

Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach

Antiviral Therapy · مجلد 28 (5) · 13596535231199838-13596535231199838

Background The COVID-19 pandemic has led to significant loss of life and economic disruption worldwide. Currently, there are limited effective treatments available for this disease. SARS-CoV-2 RNA-dependent RNA polymerase (SARS-CoV-2 RdRp) has been identified as a potential target for drug development against COVID-19. Natural products have been shown to possess antiviral properties, making them a promising source for developing drugs against SARS-CoV-2. Objectives The objective of this study is to identify the most effective natural inhibitors of SARS-CoV-2 RdRp among a set of 4924 African natural products using a multi-phase in silico approach. Methods The study utilized remdesivir (RTP), the co-crystallized ligand of RdRp, as a starting point to select compounds that have the most similar chemical structures among the examined set of compounds. Molecular fingerprints and structure similarity studies were carried out in the first part of the study. The second part of the study included molecular docking against SARS-CoV-2 RdRp (PDB ID: 7BV2) and Molecular Dynamics (MD) simulations including the calculation of RMSD, RMSF, Rg, SASA, hydrogen bonding, and PLIP. Moreover, the calculations of Molecular mechanics with generalised Born and surface area solvation (MM-GBSA) Lennard-Jones and Columbic electrostatic interaction energies have been conducted. Additionally, in silico ADMET and toxicity studies were performed to examine the drug likeness degrees of the selected compounds. Results Eight compounds were identified as the most effective natural inhibitors of SARS-CoV-2 RdRp. These compounds are kaempferol 3-galactoside, kaempferol 3- O- β-D-glucopyranoside, mangiferin methyl ether, luteolin 7- O- β-D-glucopyranoside, quercetin- O- β-D-3-glucopyranoside, 1-methoxy-3-indolylmethyl glucosinolate, naringenin, and asphodelin A 4’- O- β-D-glucopyranoside. Conclusion The results of this study provide valuable information for the development of natural product-based drugs against COVID-19. However, the elected compounds should be further studied in vitro and in vivo to confirm their efficacy in treating COVID-19.

COVID-19 pandemicnatural product inhibitorsremdesivirstructural similarity
مقالوصول مفتوح20238استشهاد· Semantic Scholar

Therapeutic Switching of Rafoxanide: a New Approach To Fighting Drug-Resistant Bacteria and Fungi

Microbiology Spectrum · مجلد 11 (4) · e0267922-e0267922

The drug repurposing strategy is an alternative approach to reducing drug development timelines with low cost, especially during outbreaks of disease caused by drug-resistant pathogens. Rafoxanide can disrupt the abilities of bacterial and fungal cells to adapt to stress conditions. The coadministration of antibiotics with rafoxanide can prevent the failure of treatment of both resistant bacteria and fungi, as the resistant pathogens could be made sensitive upon treatment with rafoxanide. From our findings, we anticipate that pharmaceutical companies will be able to utilize new combinations against resistant pathogens.

rafoxanidedrug repurposingantimicrobial resistancedrug-resistant bacteria
مراجعةوصول مفتوح2022195استشهاد· Semantic Scholar

Thiazole: A Versatile Standalone Moiety Contributing to the Development of Various Drugs and Biologically Active Agents

Molecules · مجلد 27 (13) · 3994-3994

For many decades, the thiazole moiety has been an important heterocycle in the world of chemistry. The thiazole ring consists of sulfur and nitrogen in such a fashion that the pi (π) electrons are free to move from one bond to other bonds rendering aromatic ring properties. On account of its aromaticity, the ring has many reactive positions where donor-acceptor, nucleophilic, oxidation reactions, etc., may take place. Molecules containing a thiazole ring, when entering physiological systems, behave unpredictably and reset the system differently. These molecules may activate/stop the biochemical pathways and enzymes or stimulate/block the receptors in the biological systems. Therefore, medicinal chemists have been focusing their efforts on thiazole-bearing compounds in order to develop novel therapeutic agents for a variety of pathological conditions. This review attempts to inform the readers on three major classes of thiazole-bearing molecules: Thiazoles as treatment drugs, thiazoles in clinical trials, and thiazoles in preclinical and developmental stages. A compilation of preclinical and developmental thiazole-bearing molecules is presented, focusing on their brief synthetic description and preclinical studies relating to structure-based activity analysis. The authors expect that the current review may succeed in drawing the attention of medicinal chemists to finding new leads, which may later be translated into new drugs.

thiazolethiazole derivativesheterocyclic compoundsdrug development
مقالوصول مفتوح202282استشهاد· Semantic Scholar

Quantum Dots: An Emerging Approach for Cancer Therapy

Frontiers in Materials · مجلد 8

Nanotechnology is indisputably a scientific technique that offers the prospect of new therapies, and hope, for the treatment of malignant illnesses. It is a novel technology that offers new approaches for the diagnosis and management of diverse diseases. Although the discovery of Quantum dots (QD) nano-transporters has already led to a few positive developments, QD nano-transporters are still at their initial stage, though have yet proven valuable to society. The excertion of QD indicates conversion in natural imaging along with photograph have established incredible suitability in bio-imaging, new drug development, targeted gene deliverance, biosensing, photodynamic treatment as well as diagnosis. The present review aimed to confer the significance of QD in diagnosis as well as in management of cancer. This review aims to impart fundamental insight as well as conception of QD its merits, properties, utilization as well as mode of action. This review highlight of different designing schemes of QD like hydrothermal, drop-casting, ultrasonic, solvothermal, spin-coating, atomic layer desorption, layer by layer, polymethylmethacrylate aided-transfer, electrochemical, ion beam sputtering deposition. Moreover, we have elaborated on the diverse researches related to cytotoxic examination to reveal that QDs are harmless. Concisely, the present review summarizes the fabrication schemes, current research and utilization of QD in cancer treatment.

quantum dotscancer therapynanomedicinequantum dot fabrication
مراجعةوصول مفتوح202234استشهاد· Semantic Scholar

Discovery, Development, Inventions and Patent Review of Fexinidazole: The First All-Oral Therapy for Human African Trypanosomiasis

Pharmaceuticals · مجلد 15 (2) · 128-128

Human African trypanosomiasis (HAT or 'sleeping sickness') is a neglected tropical disease. If untreated, it is always fatal and leads to death. A few treatments are available for HAT, but most of them require a skilled professional, which increases the financial burden on the patient. Recently, fexinidazole (FEX) has been approved by the European Medicine Agency (EMA) and the United States Food and Drug Administration (USFDA) as the first all-oral therapy for the treatment of stage-1 (hemolymphatic) as well as stage-2 (meningoencephalitic) of HAT. Before the FEX approval, there were separate treatments for stage-1 and stage-2 of HAT. This study reviews the discovery, development timeline, inventions, and patent literature of FEX. It was first approved by EMA and USFDA in 2018 and 2021, respectively. FEX was also added to the World Health Organization's list of essential drugs in 2019. The patent literature search revealed many types of patents/patent applications (compound, salt, process, method of treatment, drug combinations, and compositions) related to FEX, which have been summarized in this article. The authors foresee a great scope to develop more inventions based on FEX (novel salts, polymorphs, drug conjugates, cyclodextrin complex, etc.) for the treatment of many protozoal diseases (Leishmaniasis and Chagas disease), inflammatory diseases, and other microbial infections. New combinations of FEX with other treatments of HAT may also provide fruitful results. This review might be useful to the scientists working on the HAT and other neglected diseases to develop novel inventions and innovations of therapeutic relevance.

fexinidazolesleeping sicknessall-oral therapydrug development
مقالوصول مفتوح202214استشهاد· Semantic Scholar

Integrated Machine Learning and Chemoinformatics-Based Screening of Mycotic Compounds against Kinesin Spindle ProteinEg5 for Lung Cancer Therapy

Molecules · مجلد 27 (5) · 1639-1639

Among the various types of cancer, lung cancer is the second most-diagnosed cancer worldwide. The kinesin spindle protein, Eg5, is a vital protein behind bipolar mitotic spindle establishment and maintenance during mitosis. Eg5 has been reported to contribute to cancer cell migration and angiogenesis impairment and has no role in resting, non-dividing cells. Thus, it could be considered as a vital target against several cancers, such as renal cancer, lung cancer, urothelial carcinoma, prostate cancer, squamous cell carcinoma, etc. In recent years, fungal secondary metabolites from the Indian Himalayan Region (IHR) have been identified as an important lead source in the drug development pipeline. Therefore, the present study aims to identify potential mycotic secondary metabolites against the Eg5 protein by applying integrated machine learning, chemoinformatics based in silico-screening methods and molecular dynamic simulation targeting lung cancer. Initially, a library of 1830 mycotic secondary metabolites was screened by a predictive machine-learning model developed based on the random forest algorithm with high sensitivity (1) and an ROC area of 0.99. Further, 319 out of 1830 compounds screened with active potential by the model were evaluated for their drug-likeness properties by applying four filters simultaneously, viz., Lipinski's rule, CMC-50 like rule, Veber rule, and Ghose filter. A total of 13 compounds passed from all the above filters were considered for molecular docking, functional group analysis, and cell line cytotoxicity prediction. Finally, four hit mycotic secondary metabolites found in fungi from the IHR were screened viz., (-)-Cochlactone-A, Phelligridin C, Sterenin E, and Cyathusal A. All compounds have efficient binding potential with Eg5, containing functional groups like aromatic rings, rings, carboxylic acid esters, and carbonyl and with cell line cytotoxicity against lung cancer cell lines, namely, MCF-7, NCI-H226, NCI-H522, A549, and NCI H187. Further, the molecular dynamics simulation study confirms the docked complex rigidity and stability by exploring root mean square deviations, root mean square fluctuations, and radius of gyration analysis from 100 ns simulation trajectories. The screened compounds could be used further to develop effective drugs against lung and other types of cancer.

Eg5kinesin spindle proteinlung cancerfungal secondary metabolites